Tag Archives: ovarian

Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure

Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »

AstraZeneca, Merck's Lynparza plows ahead in ovarian cancer with $1B-plus approval, phase 3 data

The year may be winding down, but AstraZeneca and Merck’s Lynparza sure isn’t. It picked up a blockbuster new approval late Wednesday and followed up the act by posting positive phase 3 data Thursday morning. U.S. regulators green-lighted the fast-growing PARP inhibitor in BRCA-mutated ovarian cancer patients who’ve responded partially or completely to an initial… Read More »